Payment overview · 2025
General Payments
$3,017.21
117 reported records · 30 companies
Healthcare provider profile · identity verified
Mohammad S Hussain, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · AMITYVILLE, NY · NPI 1710051537
Verified facts
What the public records show
CMS Open Payments records show Mohammad S Hussain, M.D. received $3,017.21 in general payments during 2025 across 117 reported records.
ABBVIE INC. accounted for 12.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 46 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Airsupra, Farxiga, Ibsrela, Jardiance, Kerendia, Linzess, Mounjaro, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
Ardelyx, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IBSRELA as an associated drug or biological on 59980 records involving 18215 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Ibsrela by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AIRSUPRA as an associated drug or biological on 165148 records involving 56069 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Airsupra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 186 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 281 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $369.66 | 12.2% | 15 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $303.10 | 10.1% | 10 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $232.35 | 7.7% | 8 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $184.82 | 6.1% | 6 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $171.86 | 5.7% | 11 | 2025 |
| Ceribell, Inc. | Unresolved — no canonical attribution shown | $171.36 | 5.7% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $159.70 | 5.3% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $149.29 | 5.0% | 6 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $146.40 | 4.8% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $141.28 | 4.7% | 7 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $130.70 | 4.3% | 6 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $112.33 | 3.7% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $107.27 | 3.6% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $76.41 | 2.5% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $67.80 | 2.2% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $56.47 | 1.9% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $56.02 | 1.9% | 3 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $55.26 | 1.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $53.29 | 1.8% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $44.99 | 1.5% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.49 | 1.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.00 | 1.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $26.82 | 0.9% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $26.66 | 0.9% | 1 | 2025 |
| RGH Enterprises LLC | Unresolved — no canonical attribution shown | $23.41 | 0.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.02 | 0.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.96 | 0.6% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.99 | 0.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.16 | 0.5% | 1 | 2025 |
| Medicure Pharma Inc. | Unresolved — no canonical attribution shown | $13.34 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,009.86 | 116 |
| Education | $7.35 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $267.34 | 11 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $232.35 | 8 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $194.11 | 7 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $184.82 | 6 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $171.86 | 11 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $171.59 | 3 | 2025 |
Source payment records
|
|||||
| POCKET EEG DEVICE Normalized: pocket eeg device |
Device | Ceribell, Inc. | $171.36 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $163.35 | 2 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $146.40 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $141.28 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $130.94 | 8 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $130.70 | 6 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $116.75 | 8 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $112.33 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $107.13 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $76.41 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $67.80 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $56.47 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $56.02 | 3 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $55.26 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $53.99 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $53.29 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $53.29 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $53.29 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $48.33 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $42.95 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $41.83 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $41.04 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $39.49 | 2 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $31.14 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $30.00 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $26.82 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $26.66 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $26.66 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $22.60 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $22.60 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $22.60 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $22.39 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.96 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.96 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.16 | 1 | 2025 |
Source payment records
|
|||||
| Zypitamag Normalized: zypitamag |
Drug | Medicure Pharma Inc. | $13.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AIRSUPRA airsupra |
2025 | Airsupra | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 186 | exact normalized | Medicare Part D |
| IBSRELA ibsrela |
2025 | Ibsrela | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 108 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 32 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 63 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 145 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 51 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 44 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
32 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Ardelyx, Inc. Exact reporting entity; no affiliate inference |
2025 | IBSRELA open payments reported associated product |
CMS Open Payments — General Payments 59980 supporting records · 18215 recipient NPIs · example record 1247828901 |
Ibsrela · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | AIRSUPRA open payments reported associated product |
CMS Open Payments — General Payments 165148 supporting records · 56069 recipient NPIs · example record 1206131344 |
Airsupra · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
186 | 52 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
108 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
44 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
108 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
63 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
145 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
51 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
281 | 65 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 587 | 158 |
| Furosemide | Furosemide | 462 | 137 |
| Levothyroxine Sodium | Levothyroxine Sodium | 402 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 350 | 98 |
| Metoprolol Succinate | Metoprolol Succinate | 343 | 94 |
| Gabapentin | Gabapentin | 342 | 97 |
| Dexamethasone | Dexamethasone | 297 | 142 |
| Metformin Hcl | Metformin Hcl | 289 | 81 |
| Eliquis | Apixaban | 281 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 276 | 110 |
| Tamsulosin Hcl | Tamsulosin Hcl | 272 | 76 |
| Metoprolol Tartrate | Metoprolol Tartrate | 269 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 250 | 89 |
| Potassium Chloride | Potassium Chloride | 242 | 78 |
| Azithromycin | Azithromycin | 204 | 118 |
| Simvastatin | Simvastatin | 204 | 57 |
| Meloxicam | Meloxicam | 189 | 72 |
| Farxiga | Dapagliflozin Propanediol | 186 | 52 |
| Omeprazole | Omeprazole | 178 | 61 |
| Famotidine | Famotidine | 168 | 59 |
| Hydralazine Hcl | Hydralazine Hcl | 166 | 41 |
| Warfarin Sodium | Warfarin Sodium | 165 | 16 |
| Losartan Potassium | Losartan Potassium | 160 | 54 |
| Lisinopril | Lisinopril | 157 | 35 |
| Januvia | Sitagliptin Phosphate | 153 | 18 |
| Ozempic | Semaglutide | 145 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 138 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 137 | 64 |
| Montelukast Sodium | Montelukast Sodium | 125 | 49 |
| Alprazolam | Alprazolam | 123 | 38 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 123 | 33 |
| Cephalexin | Cephalexin | 114 | 77 |
| Jardiance | Empagliflozin | 108 | 28 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 105 | 11 |
| Spironolactone | Spironolactone | 102 | 20 |
| Trazodone Hcl | Trazodone Hcl | 102 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 100 | 17 |
| Tramadol Hcl | Tramadol Hcl | 100 | 41 |
| Meclizine Hcl | Meclizine Hcl | 99 | 38 |
| Metolazone | Metolazone | 98 | 33 |
| Xarelto | Rivaroxaban | 96 | 17 |
| Tresiba Flextouch U-200 | Insulin Degludec | 91 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 89 | 48 |
| Divalproex Sodium | Divalproex Sodium | 88 | suppressed |
| Carvedilol | Carvedilol | 86 | 22 |
| Donepezil Hcl | Donepezil Hcl | 85 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 85 | 23 |
| Finasteride | Finasteride | 77 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 77 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 20 |
| Levetiracetam | Levetiracetam | 72 | 15 |
| Nystatin | Nystatin | 71 | 32 |
| Latanoprost | Latanoprost | 70 | 16 |
| Allopurinol | Allopurinol | 69 | 27 |
| Alendronate Sodium | Alendronate Sodium | 66 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 66 | 29 |
| Mounjaro | Tirzepatide | 63 | 11 |
| Enalapril Maleate | Enalapril Maleate | 62 | suppressed |
| Prednisone | Prednisone | 61 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 16 |
| Memantine Hcl | Memantine Hcl | 60 | 17 |
| Mirtazapine | Mirtazapine | 60 | 23 |
| Breo Ellipta | Fluticasone/Vilanterol | 59 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 58 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 57 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 56 | 13 |
| Olanzapine | Olanzapine | 55 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 52 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 52 | 17 |
| Methocarbamol | Methocarbamol | 52 | 29 |
| Myrbetriq | Mirabegron | 52 | suppressed |
| Rybelsus | Semaglutide | 51 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 50 | suppressed |
| Ramipril | Ramipril | 50 | 13 |
| Sertraline Hcl | Sertraline Hcl | 50 | 19 |
| Mupirocin | Mupirocin | 49 | 24 |
| Labetalol Hcl | Labetalol Hcl | 48 | 13 |
| Diclofenac Potassium | Diclofenac Potassium | 47 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 11 |
| Rexulti | Brexpiprazole | 45 | suppressed |
| Ssd | Silver Sulfadiazine | 45 | 12 |
| Baclofen | Baclofen | 44 | 14 |
| Klor-Con M20 | Potassium Chloride | 44 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 11 |
| Torsemide | Torsemide | 44 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | 19 |
| Entresto | Sacubitril/Valsartan | 43 | suppressed |
| Diazepam | Diazepam | 42 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | 18 |
| Atenolol | Atenolol | 40 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 39 | 11 |
| Lactulose | Lactulose | 38 | 18 |
| Metformin Er Gastric | Metformin Hcl | 38 | 12 |
| Procrit | Epoetin Alfa | 37 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 36 | 26 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 35 | 15 |
| Novolog | Insulin Aspart | 34 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 33 | 13 |
| Clonazepam | Clonazepam | 33 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 19 |
| Fluconazole | Fluconazole | 32 | 12 |
| Linzess | Linaclotide | 32 | 13 |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 32 | 12 |
| Glimepiride | Glimepiride | 31 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Colchicine | Colchicine | 30 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 28 | suppressed |
| Digoxin | Digoxin | 28 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 28 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 27 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 27 | suppressed |
| Nisoldipine | Nisoldipine | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 26 | 22 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Ibsrela | Tenapanor Hcl | 22 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 21 | 12 |
| Oxycontin | Oxycodone Hcl | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Folic Acid | Folic Acid | 20 | suppressed |
| Methimazole | Methimazole | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | 17 |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Haloperidol | Haloperidol | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Brilinta | Ticagrelor | 18 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Gemtesa | Vibegron | 18 | suppressed |
| Kerendia | Finerenone | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Trulance | Plecanatide | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 16 | 11 |
| Repaglinide | Repaglinide | 16 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 11 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | suppressed |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 12 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Airsupra | Albuterol Sulfate/Budesonide | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,017.21 · 117 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, ARISTADA, Auvelity, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, FANAPT, FARXIGA, FUROSCIX, GARDASIL 9, GVOKE HYPOPEN, HETLIOZ, IBSRELA, Indigo System, JARDIANCE, Kerendia, LEQVIO, LINZESS, LYBALVI, M-M-R II, MOUNJARO, OTEZLA, Ozempic, POCKET EEG DEVICE, PREVNAR 20, PURIFIED CORTROPHIN GEL, QULIPTA, REPATHA, REXULTI, Rybelsus, Symbravo, TRELEGY ELLIPTA, TZIELD, UBRELVY, VERQUVO, VRAYLAR, XIFAXAN, YUPELRI, ZEPBOUND, ZORYVE, Zypitamag | 19 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Airsupra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error